Gilead Sciences Korea Appoints Choi Jaeyeon as New CEO

Gilead Sciences announced on the 14th that Choi Jae-yeon will be appointed as the new head of Korea starting from the 1st of next month.

Choi Jae-yeon, New CEO of Gilead Sciences Korea [Photo by Gilead Sciences Korea]

As the new head, Choi will oversee Gilead's domestic business and will drive business development (BD) in areas including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, antifungal, and oncology.

Choi earned an MBA from Northwestern University's Kellogg School of Management and has over 20 years of experience in the pharmaceutical industry at Eli Lilly and MSD* (Merck & Co., USA). During this time, he held various leadership roles across multiple regions including the United States, China, and Taiwan, covering commercial, human resources, pricing, and policy sectors.

He worked at Eli Lilly for 11 years, serving as Marketing Director at Lilly Korea, and in 2017, he held positions such as Senior Director of External Affairs and Executive Director of the Oncology Business Unit at MSD Korea, achieving outstanding results in the oncology field. Prior to joining Gilead, he led remarkable business growth for two consecutive years as Managing Director of MSD Taiwan.

Choi Jae-yeon, the new head, said, “I am pleased to join Gilead Sciences Korea and continue the company’s mission to improve the lives and save the lives of patients in the Asia region.” He added, “As a pharmaceutical professional who has always deeply embraced the noble mission of the industry and considered medical innovation for all through public-private partnerships, I am delighted to join Gilead, a company known for placing patients at the center of its work and valuing contributions to the local community.”

This content was produced with the assistance of AI translation services.